Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older

NCT06904222 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infection

Interventions

BIOLOGICAL: Low dose antigen of LYB005 without A01B adjuvant
BIOLOGICAL: Low dose antigen of LYB005 with A01B adjuvant
BIOLOGICAL: Middle dose antigen of LYB005 without A01B adjuvant
BIOLOGICAL: Middle dose antigen of LYB005 with A01B adjuvant
BIOLOGICAL: High dose antigen of LYB005 without A01B adjuvant
BIOLOGICAL: High dose antigen of LYB005 with A01B adjuvant
BIOLOGICAL: Placebo

Sponsor

Guangzhou Patronus Biotech Co., Ltd.